Spyre Therapeutics, Inc. — Director's Dealing 2016

Apr 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-04-12

Reporting Person: LILLY ELI & CO (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-04-12	Common Stock	C	2010924	—	Acquired	2068543	Indirect
2016-04-12	Common Stock	P	500000	$10	Acquired	2568543	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-04-12	Series A Preferred Stock	$0.0	C	890476	Disposed		Common Stock (890476.0)	Indirect
2016-04-12	Series B Preferred Stock	$0.0	C	1120448	Disposed		Common Stock (1120448.0)	Indirect

Footnotes

F1: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F2: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.